Detalles de la búsqueda
1.
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Allergy
; 78(11): 2875-2891, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37455359
2.
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
Dermatology
; 237(1): 46-55, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-31962340
3.
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
J Am Acad Dermatol
; 78(4): 741-748, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066271
4.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
J Am Acad Dermatol
; 81(6): 1405-1409, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399223
5.
Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid.
Dermatol Surg
; 39(6): 915-22, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23464798
6.
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
J Dermatolog Treat
; 32(3): 302-309, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31581919
7.
Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry.
J Dermatolog Treat
; 32(8): 907-915, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32027197
8.
US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.
J Dermatolog Treat
; 31(4): 333-341, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31035822
9.
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
J Dermatol
; 46(9): 752-758, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31342560
10.
Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.
Dermatol Ther (Heidelb)
; 8(1): 17-32, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29218492
11.
Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis.
J Dermatolog Treat
; 28(3): 200-205, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27541729
12.
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Adv Ther
; 34(6): 1327-1339, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28397079
13.
Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.
Dermatol Ther (Heidelb)
; 6(4): 627-638, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573260
14.
Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.
Dermatol Ther (Heidelb)
; 6(4): 639-647, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27576559
15.
Auvi-Q versus EpiPen: preferences of adults, caregivers, and children.
J Allergy Clin Immunol Pract
; 1(3): 266-72.e1-3, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24565484
16.
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Adv Ther
; 34(7): 1772, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28589404
Resultados
1 -
16
de 16
1
Próxima >
>>